Name of this trial: BGB-11417-303/CLL-RR1
What type of cancer is this for? Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Who is this trial for? Relapsed and/or Refractory
What biomarkers are involved? CLL Cytogenics (eg, del(17p), del(11q), del(13q), and trisomy 12), complex karyotype, and the mutational status of relevant genes such as IGHV, TP53, and other CLL-related prognosis mutations.
What is the National Clinical Trial #? NCT06943872; https://www.clinicaltrials.gov/study/NCT06943872
Brief summary of this trial: A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Need to know: Have confirmed diagnosis of CLL/SLL and received one or more prior therapies for CLL/SLL. For reach line of therapy, patients must have received at least 2 cycles of therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Name of this trial: CELESTIAL-RRMCL
What type of cancer is this for? Mantle Cell Lymphoma
Who is this trial for? Patients who have relapsed or refractory Mantle cell lymphoma.
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06742996
Brief summary of this trial: Phase 3 randomized, double-blinded trial of sonrotoclax plus zanubrutinib VS. placebo plus Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.
Need to know: Patients may have had 1-5 different lines of prior therapy. These medications are both oral medications but do require long clinic visits in the beginning of the study. No prior allogenic stem cell transplant within 6 months to starting trial and no prior autologous stem cell transplant within 3 months of starting the trial.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: Olympia-3
What type of cancer is this for? Untreated patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of this trial? 3
Who is the trial for? Newly diagnosed patients with Diffuse large B-cell Lymphoma.
What biomarkers/mutations are necessary? CD20+
What is the National Clinical Trials info? NCT06091865
Brief summary of Trial: Patients who are eligible will receive standard of care chemotherapy (CHOP) plus investigational drug Odronextamab. Odronextamab is the investigation drug and will require frequent infusions/frequent check-in visits due to step-up dosing during the first 6 weeks. After the first 6 weeks treatment will be less frequent and may be given at any of our Cancer and Hematology centers. First 6 weeks will be done at our Grand Rapids site and will require patient to stay within 20 mins of hospital. Trial will supplement monies required for patients to be close to hospital.
Need to know: See above. Flexibility in staying at hotel near hospital in Grand Rapids is required and covered by study for 1-2 nights each week for the first 6 weeks. Newly being treated for this type of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]